Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface ...

After treating a tumor with chemotherapy and radiotherapy, cells known as senescent cells can appear. These are cells that do ...

Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of ...

Studies of living participants and postmortem brains confirm that gene expansion is a promising target for HD prevention ...

For decades, we’ve believed the bright redness of sunburn — along with its irritating sting and peeling skin — was the result ...

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Researchers have discovered that mouse PD-1 is significantly weaker than human PD-1, calling into question their reliability ...

Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...

BCL-2 inhibitors, such as venetoclax (Venclexta) work by targeting the BCL-2 protein, which plays a key role in preventing apoptosis, or programmed cell death. According to John Seymour, MD, ...

Necroptosis, a pathway responsible for programmed ... death, necroptosis shares features of both apoptosis (natural cell breakdown) and necrosis (injury-related cell damage). Receptor-interacting ...

This executive interview, sponsored by BeiGene, is with Jan-Henrik Terwey, Vice President, Medical Affairs Europe at BeiGene.